Mankind Pharma Ltd shares surged nearly 3% on Wednesday, March 18, following the announcement of acquiring the Rivotril brand from Roche for the Indian market. According to latest market data, the stock was trading at ₹2,121.90 on BSE, up 2.63% from the previous close, having touched an intraday high of ₹2,117.60 and low of ₹2,056.20. In the previous trading session, the share closed down 1.17% at ₹2,067.45. The stock has declined 19.60% in the last six months, indicating recent challenges in performance, though it currently trades 22.44% below its 52-week high of ₹2,726.75 and 4.97% above its 52-week low of ₹2,014.85. With a market capitalisation of ₹87,309.06 crore, the stock's performance reflects investor confidence in the company's strategic expansion into the CNS therapeutic segment.
The company has secured exclusive rights to manufacture, market and distribute Rivotril in India, a move that will strengthen its presence in the chronic and central nervous system (CNS) therapies segment. Rivotril is the innovator/reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions including seizures, anxiety disorders and other neurological conditions. The acquisition adds a well-established brand with a strong clinical legacy and specialist recall to Mankind Pharma's portfolio, complementing its existing neuro/CNS offerings. According to latest reports, this acquisition represents a focused expansion into the CNS therapeutic segment, with Rivotril often regarded as a textbook brand in its category with strong clinical legacy. The deal creates opportunities for future line extensions in the CNS segment, helping address evolving patient and physician needs, positioning Mankind Pharma to capitalize on strong opportunities through its established platform.
According to Moneycontrol, Atish Majumdar, Senior President, Sales & Marketing, Mankind Pharma Specialty Business, stated that this acquisition is aligned with the company's strategy to strengthen its chronic and specialty therapy footprint. The company leverages its large field force of 17,700+ professionals and nationwide distribution network to build the brand and support physicians in delivering better outcomes for patients across India. Mankind Pharma currently engages with over five lakh doctors and has built a strong prescription share in the Indian pharmaceutical market, enabling deep penetration across urban and semi-urban markets. The company's subsidiary, The Beverage Company Proprietary, has also executed an agreement to acquire a 100% equity stake in Crickley Dairy Proprietary, South Africa, for ₹131.4 crore, aiming to diversify its product portfolio into new categories including value-added dairy and juice-based drinks.
For the December quarter, as reported by CNBC TV18, the company posted strong financial results with net profit growing 7.5% year-on-year to ₹408.7 crore from ₹380.2 crore in Q3FY25. Revenue increased 11.5% YoY to ₹3,567 crore from ₹3,198 crore last year. EBITDA rose 12.7% to ₹919.6 crore from ₹816.2 crore, with EBITDA margin standing at 25.8%, compared with 25.5% in the same quarter last year. The company's subsidiary, The Beverage Company Proprietary, has also executed an agreement to acquire a 100% equity stake in Crickley Dairy Proprietary, South Africa, for ₹131.4 crore, aiming to diversify its product portfolio into new categories including value-added dairy and juice-based drinks.
According to Moneycontrol, the deal aligns with Mankind Pharma's long-term shift toward chronic therapies, which have been growing faster than its traditional acute-care portfolio. The company has been adding specialty assets through in-licensing deals, new launches and portfolio additions, aiming to lift the contribution of chronic segments to its revenue mix. The acquisition positions Mankind Pharma to build a broader CNS platform with scope for line extensions and expanded indications. Additionally, as reported by ScanXNews, the company has completed the allotment of 23,256 equity shares under its Employee Stock Option Plan 2022 on March 16, 2026, at an exercise price of ₹860.00 per share, expanding its paid-up share capital from ₹41,28,05,072 to ₹41,28,28,328. The company's subsidiary, The Beverage Company Proprietary, has also executed an agreement to acquire a 100% equity stake in Crickley Dairy Proprietary, South Africa, for ₹131.4 crore, aiming to diversify its product portfolio into new categories including value-added dairy and juice-based drinks.
